S&P 500 hits a fresh record high on stronger economic growth, Nvidia pares losses
In a remarkable display of market confidence, AbbVie Inc (NYSE:ABBV). stock has reached an all-time high, climbing to a price level of $215.84. According to InvestingPro data, the pharmaceutical giant, now valued at nearly $380 billion, has delivered a 24.2% return over the past year. The company has maintained dividend payments for 13 consecutive years, currently offering a 3.1% yield. Investors have shown increasing enthusiasm for AbbVie’s prospects, propelling the stock to new heights and eclipsing all previous records. With a robust gross profit margin of 70.3% and strong revenue growth expectations, the company’s strategic initiatives and product pipeline appear to be key drivers of this sustained upward trend. InvestingPro analysis reveals 14 additional key insights about AbbVie’s financial health and market position, available to subscribers.
In other recent news, AbbVie announced a licensing agreement with Gubra to acquire the long-acting Amylin analogue, GUB14295, which is currently in phase 1 development. This deal involves an upfront payment of $350 million and potential milestone payments up to $1.875 billion, alongside royalties on net sales. BMO Capital Markets maintained an Outperform rating for AbbVie, with a price target of $215, acknowledging the strategic importance of this acquisition. Meanwhile, Bernstein SocGen Group kept a Market Perform rating with a $203 target, noting AbbVie’s entry into the obesity treatment market with GUBamy as a significant new opportunity. BofA Securities raised its price target for AbbVie to $223 from $200, maintaining a Neutral rating, citing the company’s robust financial prospects and entry into the obesity market as key factors.
Additionally, N-able reported fourth-quarter earnings that exceeded expectations, with adjusted earnings per share of $0.10 and revenue of $116.5 million, surpassing the consensus forecast. Despite this, N-able’s guidance for 2025 fell short of analyst projections, leading to a nearly 6% drop in shares. The company expects first-quarter revenue between $115-116 million, below the anticipated $120.4 million, and full-year 2025 revenue between $486.5-492.5 million, missing the consensus estimate of $512.2 million. CEO John Pagliuca expressed confidence in the company’s strategic investments in cyber-resilience and security leadership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.